Background: SOX genes play an important role in a number of developmental processes. Potential roles of SOXs have been demonstrated in various neoplastic tissues as tumor suppressors or promoters depending on tumor status and types. The aim of this study was to investigate the involvement of SOXs in the progression and prognosis of human prostate cancer (PCa). Methods: The gene expression changes of SOXs in human PCa tissues compared with non-cancerous prostate tissues was detected using gene expression microarray, and confirmed by real-time quantitative reverse transcriptase-polymerase chain reaction (QRT-PCR) analysis and immunohositochemistry. The roles of these genes in castration resistance were investigated in LNCaP xenograft model of PCa. Results: The microarray analysis identified three genes (SOX7, SOX9 and SOX10) of SOX family that were significantly dis-regulated in common among four PCa specimens. Consistent with the results of the microarray, differential mRNA and protein levels of three selected genes were found in PCa tissues by QRT-PCR analysis and immunohistochemistry. Additionally, we found that the immunohistochemical staining scores of SOX7 in PCa tissues with higher serum PSA level (P = 0.02) and metastasis (P = 0.03) were significantly lower than those with lower serum PSA level and without metastasis; the increased SOX9 protein expression was frequently found in PCa tissues with higher Gleason score (P = 0.02) and higher clinical stage (P < 0.0001); the down-regulation of SOX10 tend to be found in PCa tissues with higher serum PSA levels (P = 0.03) and advanced pathological stage (P = 0.01). Moreover, both univariate and multivariate analyses showed that the down-regulation of SOX7 and the up-regulation of SOX9 were independent predictors of shorter biochemical recurrence-free survival. Furthermore, we discovered that SOX7 was significantly down-regulated and SOX9 was significantly up-regulated during the progression to castration resistance. Conclusions: Our data offer the convince evidence that the dis-regulation of SOX7, SOX9 and SOX10 may be associated with the aggressive progression of PCa. SOX7 and SOX9 may be potential markers for prognosis in PCa patients. Interestingly, the down-regulation of SOX7 and the up-regulation of SOX9 may be important mechanisms for castration-resistant progression of PCa.
Background: Our recent study showed the global physiological function of the differentially expressed genes of prostate cancer in Chinese patients was different from that of other non-Chinese populations. microRNA are estimated to regulate the expression of greater than 60% of all protein-coding genes. To further investigate the global association between the transcript abundance of miRNAs and their target mRNAs in Chinese patients, we used microRNA microarray approach combined with bioinformatics and clinical-pathological assay to investigate the miRNA profile and evaluate the potential of miRNAs as diagnostic and prognostic markers in Chinese patients.Results: A total of 28 miRNAs (fold change ≥1.5;P ≤ 0.05) were differentially expressed between tumor tissue and adjacent benign tissue of 4 prostate cancer patients.10 top Differentially expressed miRNAs were validated by qRT-PCR using all 20 tissue pairs. Compared to the miRNA profile of non-Chinese populations, the current study showed that miR-23b, miR-220, miR-221, miR-222, and miR-205 maybe common critical therapeutic targets in different populations. The integrated analysis for mRNA microarray and miRNA microarray showed the effects of specifically inhibiting and/or enhancing the function of miRNAs on the gene transcription level. The current studies also identified 15 specific expressed miRNAs in Chinese patients. The clinical feature statistics revealed that miR-374b and miR-19a have significant correlations with clinical-pathological features in Chinese patients.Conclusions: Our findings showed Chinese prostate cancer patients have a common and specific miRNA expression profile compared with non-Chinese populations. The miR-374b is down-regulated in prostate cancer tissue, and it can be identified as an independent predictor of biochemical recurrence-free survival.
Prostate cancer (PC) is the most frequently diagnosed cancer in men and it is difficult to achieve the desired therapeutic effect through traditional chemotherapy. Thus, it is necessary to develop advanced strategies to treat PC. Functionalized nanoparticles have been developed as a unique tumor-targeted delivery platform for PC therapy. In this study, tumor-targeted RGD-silver nanoparticles (RGD-Ag NPs) were prepared, in which RGD could specially bind with its receptor αvβ3 integrin over-expressed on LNCaP cells. RGD-Ag NPs were adopted to load adriamycin (Am) to prepare functionalized silver nanoparticles (RGD-Ag@Am). The average particle size of RGD-Ag@Am was about 65 nm and kept under 90 nm during the 8-day trial period. LNCaP cells showed greater uptake in RGD-Ag@Am group compared to Ag@Am group, indicating active targeting of carrier RGD-Ag NPs could effectively enhance the uptake of Am in LNCaP cells. RGD-Ag@Am entered LNCaP cells in a clathrin-mediated energy-dependent manner and demonstrated an excellent pH-response release of Am under the acidic condition, which was conducive to enhancing the distribution of Am in the tumor microenvironment. RGD-Ag@Am inhibited the proliferation and invasion of LNCaP cells and induced LNCaP cell apoptosis which probably promotes the production of reactive oxygen species (ROS). It was noteworthy that RGD-Ag@Am exhibited greater anti-cancer activity in comparison with free Am and Ag@Am in the LNCaP cell model, indicating that RGD-Ag NPs had the ability to enhance the anti-cancer efficacy of Am. These findings showed that RGD-Ag@Am has promising potential for use in PC therapy.